UK heart charity banks on regenerative techs with £50m R&D programme
This article was originally published in Clinica
The British Heart Foundation (BHF) has launched a programme of research into the potential of regenerative medicine to treat heart failure resulting from infarction, or heart attack.
You may also be interested in...
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.
Sawai’s sales increased on the back of a good performance from recently-launched products in the first nine months of its financial year. However, given the competitive environment the Japanese company is continuing to stick to its full-year forecasts.